Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
Ist Teil von
The New England journal of medicine, 2008-12, Vol.359 (23), p.2429-2441
Ort / Verlag
Waltham, MA: Massachusetts Medical Society
Erscheinungsjahr
2008
Quelle
MEDLINE
Beschreibungen/Notizen
Patients with chronic hepatitis C who did not have a sustained viral response to peginterferon and ribavirin were randomly assigned to receive low-dose peginterferon or no treatment for 3.5 years. The clinical and histologic outcomes were not better in patients treated with peginterferon. These findings do not support the use of long-term peginterferon in patients who do not have a sustained virologic response to initial therapy.
Patients with chronic hepatitis C who did not have a sustained viral response to peginterferon and ribavirin were randomly assigned to receive low-dose peginterferon or no treatment for 3.5 years. The clinical and histologic outcomes were not better in patients treated with peginterferon.
More than 3 million Americans and 170 million persons worldwide are chronically infected with hepatitis C virus (HCV),
1
,
2
which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease.
3
Among adults in the Western world, chronic hepatitis C is a major cause of cirrhosis and a major indication for liver transplantation. Chronic hepatitis C has contributed also to the increasing incidence of hepatocellular carcinoma, for which few satisfactory therapies exist.
4
Therapy with peginterferon and ribavirin for 24 to 48 weeks leads to a sustained loss of serum HCV RNA (termed a sustained virologic response), . . .